Combining TGF-β inhibitors with standard chemotherapy or novel targeted therapies may enhance treatment efficacy, potentially reversing EMT characteristics and making tumor cells more susceptible to cytotoxic agents [75,76]. The gene discussed is TGFB1; the disease is neoplasm.